Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (Q2)Oct 31, 2025 | (Q1)Jul 31, 2025 | (FY)Apr 30, 2025 | (Q4)Apr 30, 2025 | (Q3)Jan 31, 2025 | (Q2)Oct 31, 2024 | (Q1)Jul 31, 2024 | (FY)Apr 30, 2024 | (Q4)Apr 30, 2024 | (Q3)Jan 31, 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | -3.33%270.86M | -3.33%270.43M | 11.38%1.06B | -8.40%250.59M | -0.29%253.68M | 26.40%280.19M | 35.90%279.76M | 22.85%955.52M | 48.01%273.57M | 59.21%254.42M |
| Cost of revenue | 6.24%884.49M | 27.08%832.56M | ||||||||
| Gross profit | 46.18%179.74M | 0.26%122.96M | ||||||||
| Operating expense | -16.30%218.17M | -7.76%240.12M | 19.50%83.43M | -11.37%225.15M | -5.86%220.82M | 24.04%260.65M | 32.19%260.3M | 0.93%69.81M | 153.41%254.02M | 60.84%234.56M |
| Selling and administrative expenses | ---- | ---- | 20.15%78.01M | ---- | ---- | ---- | ---- | 3.48%64.93M | ---- | ---- |
| -Selling and marketing expense | ---- | ---- | 26.12%43.8M | ---- | ---- | ---- | ---- | -6.13%34.73M | ---- | ---- |
| -General and administrative expense | ---- | ---- | 13.29%34.21M | ---- | ---- | ---- | ---- | 17.28%30.2M | ---- | ---- |
| Other operating expenses | -16.30%218.17M | -7.58%240.58M | 7.07%6.44M | -12.28%225.64M | -5.41%222.43M | 24.04%260.65M | 32.19%260.3M | -15.86%6.02M | 147.66%257.23M | 55.56%235.14M |
| Total other operating income | ---- | --461K | -9.39%1.02M | -84.72%491K | 178.41%1.61M | ---- | ---- | 56.81%1.13M | 331.82%3.21M | -89.11%579K |
| Operating profit | 169.66%52.69M | 55.79%30.32M | 81.22%96.31M | 30.12%25.44M | 65.49%32.87M | 69.32%19.54M | 117.58%19.46M | -0.61%53.15M | 271.43%19.55M | 42.24%19.86M |
| Net non-operating interest income (expenses) | -9.68%-2.74M | -25.56%-2.76M | -41.98%-8.89M | -21.74%-3.55M | -57.65%-3.35M | -16.17%-2.5M | -15.59%-2.2M | 20.86%-6.26M | -333.33%-2.91M | 11.39%-2.12M |
| Non-operating interest income | ---- | ---- | -5.10%2.68M | ---- | ---- | ---- | ---- | 65.67%2.82M | ---- | ---- |
| Non-operating interest expense | 9.68%2.74M | 25.56%2.76M | 27.35%11.57M | 21.74%3.55M | 57.65%3.35M | 16.17%2.5M | 15.59%2.2M | -5.53%9.09M | 22.56%2.91M | -11.39%2.12M |
| Net investment income | -95.87%59K | -52.73%1.43M | ||||||||
| Gain(Loss) on financial instruments designated as cash flow hedges | ||||||||||
| Gain(Loss) on derecognition of available-for-sale financial assets | 1.97%311K | 41.86%305K | ||||||||
| Income from associates and other participating interests | 100.00%2K | 53.57%-13K | 85.60%-35K | 112.77%6K | 94.64%-14K | 106.67%1K | -135.00%-28K | -179.67%-243K | 52.53%-47K | 41.61%-261K |
| Special income (charges) | -218.25%-2.35M | 176.28%1.98M | ||||||||
| Less:Other special charges | ---- | ---- | 67.80%-19K | ---- | ---- | ---- | ---- | 85.64%-59K | ---- | ---- |
| Less:Write off | ---- | ---- | 222.86%2.37M | ---- | ---- | ---- | ---- | -163.91%-1.93M | ---- | ---- |
| Other non-operating income (expenses) | 35.92%280K | 11.96%206K | ||||||||
| Income before tax | 193.12%49.95M | 59.82%27.55M | 69.46%85.69M | 32.00%21.9M | 68.83%29.51M | 81.81%17.04M | 141.92%17.24M | 8.31%50.57M | 212.13%16.59M | 57.17%17.48M |
| Income tax | 145.14%11.01M | 88.58%8.16M | 90.27%26.65M | 26.15%9.1M | 200.21%8.43M | 39.40%4.49M | 470.58%4.33M | 44.37%14.01M | 1,283.11%7.22M | -0.14%2.81M |
| Net income | 210.30%38.94M | 50.19%19.39M | 61.49%59.04M | 36.51%12.8M | 43.69%21.08M | 104.03%12.55M | 102.80%12.91M | -1.15%36.56M | 58.22%9.38M | 76.56%14.67M |
| Net income continuous operations | 210.30%38.94M | 50.19%19.39M | 61.49%59.04M | 36.51%12.8M | 43.69%21.08M | 104.03%12.55M | 102.80%12.91M | -1.15%36.56M | 58.22%9.38M | 76.56%14.67M |
| Noncontrolling interests | 244.62%16.91M | 92.35%7.79M | 211.39%22.73M | 9,789.66%5.62M | 138.67%8.44M | 176.24%4.91M | 98.24%4.05M | 514.01%7.3M | -146.40%-58K | 1,508.18%3.54M |
| Net income attributable to the company | 188.28%22.03M | 30.92%11.6M | 24.10%36.32M | -23.90%7.18M | 13.50%12.63M | 74.71%7.64M | 104.95%8.86M | -24.48%29.26M | 62.63%9.43M | 37.62%11.13M |
| Preferred stock dividends | ||||||||||
| Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income attributable to common stockholders | 188.28%22.03M | 30.92%11.6M | 24.10%36.32M | -23.90%7.18M | 13.50%12.63M | 74.71%7.64M | 104.95%8.86M | -24.48%29.26M | 62.63%9.43M | 37.62%11.13M |
| Gross dividend payment | ||||||||||
| Basic earnings per share | 188.07%0.0507 | 30.88%0.0267 | 24.07%0.0835 | -23.96%0.0165 | 13.67%0.0291 | 74.26%0.0176 | 106.06%0.0204 | -24.47%0.0673 | 63.16%0.0217 | 37.63%0.0256 |
| Diluted earnings per share | 188.07%0.0507 | 30.88%0.0267 | 24.07%0.0835 | -23.96%0.0165 | 13.67%0.0291 | 74.26%0.0176 | 106.06%0.0204 | -24.47%0.0673 | 63.16%0.0217 | 37.63%0.0256 |
| Dividend per share | 0.00%0.025 | 0 | 0.00%0.025 | 0 | 0 | 0.00%0.025 | 0 | 0.00%0.025 | 0 | 0 |
| Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.